ADMP - Adamis Pharmaceuticals Corporation
| Previous Close | 3.45 |
| Open | 3.45 |
| Bid | 3.20 x 1000 |
| Ask | 3.50 x 900 |
| Day's Range | 3.35 - 3.47 |
| 52 Week Range | 2.35 - 5.85 |
| Volume | 296,190 |
| Avg. Volume | 777,231 |
| Market Cap | 158.426M |
| Beta | 0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.88 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.75 |
- Zacks•5 days ago
Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates
Adamis (ADMP) delivered earnings and revenue surprises of -70.59% and -5.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 days ago
Adamis: 2Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 29 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•5 days ago
Adamis Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update
Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated, “Recently, we have announced several significant achievements for our company. The Sandoz partnership for the commercialization and distribution of Symjepi™ in the U.S. will likely prove to be the most transformative for the Company. Under the agreement, Sandoz will take responsibility for sales and marketing.
- GlobeNewswire•8 days ago
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
Adamis Pharmaceuticals Corporation (ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the closing of its previously announced underwritten public offering of 11,666,667 shares of its common stock at a public offering price of $3.00 per share, as well as 1,750,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. Raymond James & Associates, Inc. acted as the sole book-running manager for the offering. B. Riley FBR acted as lead manager for the offering. H.C. Wainwright & Co. and Maxim Group LLC acted as co-managers for the offering.
- GlobeNewswire•13 days ago
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
The offering is expected to close on August 6, 2018, subject to the satisfaction of customary closing conditions. The company has also granted the underwriters a 30-day option to purchase up to 1,750,000 additional shares of its common stock. Raymond James & Associates, Inc. is acting as the sole book-running manager for the offering. B. Riley FBR is acting as lead manager for the offering. H.C. Wainwright & Co. and Maxim Group LLC are acting as co-managers for the offering.
- GlobeNewswire•13 days ago
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Aug. 01, 2018-- Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including ...
- GlobeNewswire•14 days ago
Market Trends Toward New Normal in Horizon Global, Bio-Techne, Adamis Pharmaceuticals, Kadant, Semgroup, and Provident Financial Services — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Horizon ...
- GlobeNewswire•23 days ago
Adamis Pharmaceuticals Adds Sublingual Erectile Dysfunction Product Candidate to its Pipeline
Tadalafil (Cialis®) is a drug used for treating erectile dysfunction (ED), pulmonary hypertension and benign prostatic hyperplasia (BPH). Tadalafil is in a class of drugs called phosphodiesterase-5 (PDE5) inhibitors which includes, among others, sildenafil (Viagra®) and vardenafil (Levitra®). All three drugs of these oral tablets are FDA approved and clinically indicated for the treatment of ED. Tadalafil and sildenafil are also indicated for pulmonary hypertension, but among PDE5 drugs, only tadalafil is approved for the treatment of BPH. Adamis’ first goal in development and clinical testing will be to demonstrate comparability to Cialis® and additional benefits of a rapidly acting sublingual formulation.
- Zacks•last month
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
- Zacks•last month
Adamis (ADMP) Surges Following Novartis Deal for Symjepi
Shares of Adamis (ADMP) skyrocket after the company signs a commercialization deal with Novartis for Symjepi.
- ACCESSWIRE•last month
Today's Research Reports on Stocks to Watch: Adamis Pharmaceuticals and MiMedx
NEW YORK, NY / ACCESSWIRE / July 3, 2018 / Adamis Pharmaceuticals shares exploded on Monday after announcing that it has found a commercial partner for its allergic reaction treatment Symjepi. Shares of MiMedx Group fell hard after Wall Street learned the company's CEO and COO have both resigned amidst an ongoing investigation in the company's business practices. Adamis Pharmaceuticals Corporation shares closed up 50% on Monday with about 11.5 million shares traded.
- MarketWatch•last month
Adamis has a partner to market its EpiPen competitor after a year-long search
Shares of biotech Adamis Pharmaceuticals Corp. soared more than 35% Monday, after the company said its search for a commercial partner for its competitor to Mylan N.V.’s EpiPen allergic reaction treatment is over. The Adamis (ADMP) product, called Symjepi, a syringe that’s filled with the allergic reaction treatment epinephrine, was approved by the U.S. Food and Drug Administration last July and patients have eagerly awaited its release.
- The Wall Street Journal•last month
[$$] Novartis Injects Itself Into Planned Rollout of EpiPen Competitor
Swiss drug giant Novartis AG has bought the U.S. commercial rights to sell a potentially lower-cost alternative to Mylan NV’s EpiPen, the emergency treatment for allergic reactions that has been dogged by pricing and supply challenges. Novartis’s Sandoz generic-drug unit acquired the U.S. commercial rights for an emergency shot called Symjepi from Adamis Pharmaceuticals Corp., the companies said late Sunday.
- Market Realist•last month
Adamis Pharmaceuticals Rose Almost 35% Early on July 2
On July 1, Adamis Pharmaceuticals (ADMP) announced an exclusive distribution and commercialization agreement for its Type I allergic reactions drug, Symjepi, with Novartis’ (NVS) subsidiary, Sandoz. Based on the agreement, Sandoz will hold commercial rights for the drug in the United States in exchange for upfront payment and performance-based payments. Adamis Pharmaceuticals retained the drug’s commercialization rights in markets outside the US.
- TheStreet.com•last month
Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor
to make and distribute Adamis' product to treat allergic reactions. EpiPen product, to Novartis' Sandoz Inc. division, which will distribute and sell the 0.3 and 0.15 mg versions of Symjepi, according to a press release from Adamis. As part of the deal, Novartis will pay Adamis an upfront fee and potential future milestone payments, according to a press release.
SmarterAnalyst•last monthWhy Adamis (ADMP) Is Skyrocketing Today
Adamis Pharmaceuticals (NASDAQ:ADMP) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 45% upturn. The drug maker announced a strategic distribution and commercialization agreement with Sandoz, a subsidiary of industry juggernaut Novartis, for ADMP’s EpiPen alternative, Symjepi. Sandoz will have the first right of negotiation for Symjepi internationally and ADMP will continue to be able to develop additional offerings around its injection platform, Symject. The deal comes with an upfront payment and milestones (both not disclosed) to Adamis, as well as a 50/50 profit share (US).
- GlobeNewswire•last month
Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for Symjepi
SAN DIEGO, July 01, 2018-- Adamis Pharmaceuticals Corporation announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc., a division of the Novartis ...
- ACCESSWIRE•2 months ago
Complimentary Technical Snapshots on Valeant Pharmaceuticals International and Three More Healthcare Stocks
Stock Research Monitor: QTNT, ADMP, and PETS LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration . On Wednesday, June 27, ...
- Zacks•2 months ago
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
- Zacks•3 months ago
Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
- Associated Press•3 months ago
Adamis: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of 23 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
- Zacks•4 months ago
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
Investors in Adamis Pharmaceuticals (ADMP) need to pay close attention to the stock based on moves in the options market lately.
- Simply Wall St.•4 months ago
High Growth Stocks To Invest In
Robust, high-growth companies such as Adamis Pharmaceuticals are appealing to investors for many reasons. They bring about a strong upside to your portfolio, and less downside risk as opposed toRead More...
